Panacea Biotec Ltd - PANACEA BIOTEC Share Price

Sector: Pharmaceuticals | ISIN: INE922B01023
₹ 136.65 (3.80%) icon11 Aug, 2023, 3:51:47 PM
Open
₹ 132.80
Prev. Close
₹ 131.65
Turnover(lac)
₹ 334.39
Day's High
₹ 139.00
Day's Low
₹ 129.30
52 Wk High
₹ 164.40
52 Wk Low
₹ 107.00
Book Value
₹ 49.94
Face Value
₹ 1.00
Mkt. Cap (Cr.)
₹ 836.99
P/E
0.00
EPS
0.00
Div. Yield
0.00

Panacea Biotec Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 8/11/2023 3:51:47 PM

    ₹ 136.65 5.00 3.80
  • Open
  • ₹ 132.8
  • Prev. Close
  • ₹ 131.65
  • Turnover(Lac.)
  • ₹ 334
  • Day's High
  • ₹ 139
  • Day's Low
  • ₹ 129.3
  • 52 Week's High
  • ₹ 164.4
  • 52 Week's Low
  • ₹ 107
  • Book Value
  • ₹ 49.94
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 836.99
  • P/E
  • 0
  • EPS
  • 0
  • Divi. Yield
  • 0

Panacea Biotec Ltd Corporate Actions

29 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

29 Jul , 2023

12:00 AM

15 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

01 Feb , 2023

12:00 AM

01 Feb , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

04 Nov , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

04 Nov , 2022

12:00 AM

09 Aug , 2022

12:00 AM

AGM

Announcement date: 09 Aug , 2022

View Details

10 Aug , 2022

12:00 AM

BookCloser

View Details

Panacea Biotec Ltd News and Update

Image not found
  • 11 August, 2023 |
  • 7:25 PM

The third-largest polluter in the world, France, has decided to purchase a 25% share in Adani New Industries Ltd. for an unknown sum to support green hydrogen projects there.

Image not found
Article Image
  • IIFL News Service |
  • 10 August, 2023 |
  • 7:24 PM
Image not found
  • IIFL News Service |
  • 10 August, 2023 |
  • 7:24 PM

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Panacea Biotec Ltd SHAREHOLDING SNAPSHOT
14 August , 2023 | 07:35 AM

PROMOTER - TOTAL73.59%

Indian: 73.59%

Foreign: 0%

NON-PROMOTER - TOTAL 26.41%

Institutions: 0.75%

Non-Institutions: 25.66%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Panacea Biotec Ltd FINANCIALS

Panacea Biotec Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Panacea Biotec Ltd

  • Soshil Kumar Jain
  • Chairman & Exec. Director
  • Rajesh Jain
  • Chairman & Managing Director
  • Sandeep Jain
  • Joint Managing Director
  • R L Narasimhan
  • Non-Exec. & Independent Dir.
  • N N Khamitkar
  • Non-Exec. & Independent Dir.
  • K M Lal
  • Non-Exec. & Independent Dir.
  • Vinod Goel
  • Group CFO & Company Secretary
  • Manjula Upadhyay
  • Non-Exec. & Independent Dir.
  • Mukul Gupta
  • Non-Exec. & Independent Dir.
  • Ankesh Jain
  • Whole-time Director
  • BHUPINDER SINGH
  • Non-Exec. & Independent Dir.
  • Narotam Kumar Juneja
  • Director

Summary

Indias leading research-based health management company with established research, manufacturing and marketing capabilities are collectively known as Panacea Biotec Limited (PBL), which was incorporated on 2nd February 1984 under the name of Panacea Drug (P) Ltd. A second largest vaccine producer in India has the product portfolio of highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines. The Company has collaborations and tie-ups with leading national and international research organizations and corporations. PBL has ultra modern, state-of-art production facilities at Himachal Pradesh, Punjab & Delhi for manufacturing vaccines and pharmaceutical formulations comply with the US-FDA, UK-MHRA, SAMCC and WHO-cGMP standards and it has four research and development centers. The Company also has 24 product patents, valid in more than 60 countries worldwide. The plant for vaccines production (Radicura Pharma) and pharmaceutical formulations plant (Panacea Drug P Ltd) at New Delhi were established during the year 1988 and 1989 respectively. In 1993, merger of Panacea Drugs (P) Ltd and Radicura Pharma gave the name Panacea Biotec Ltd. The Company made its Initial Public Offering (IPO) in the year of 1995 and also in the same year, PBL had formed state -of the- art Drug Delivery R&D centre at Lalru. In the year 1997,... Read More


Reports by Panacea Biotec Ltd


Reports by Panacea Biotec Ltd

Company FAQ

No Record Found